23
Jun

The Boston-based biotech Gelesis has a pair of high-profile godfathers from the research world, a fresh $12 million venture round and an intriguing new approach to treating obesity that steers clear of the brain-targeting chemicals now struggling to gain traction on the market. But the new data put out this morning fell flat with at least one of the experts in the weight-loss field.

…read more

Source: Gelesis declares a weight-loss victory, but a critic pans new therapy

    

0 No comments